Brief: Morphosys Q3 Operating Loss Narrows To EUR 29.3 Mln

Morphosys AG

16/11/2022 21:01

Nov 17 (Reuters) - MORPHOSYS AG  MORG.DE :
    * SAID ON WEDNESDAY Q3 REVENUE MORE THAN DOUBLES TO EUR 95.8
MILLION VERSUS EUR 41.2 MILLION YEAR AGO
    * 9-MONTH REVENUE UP TO EUR 196.7 MILLION VERSUS EUR 126.7
MILLION
YEAR AGO
    * Q3 RESEARCH AND DEVELOPMENT EXPENSES AT EUR 77.8 MILLION
VERSUS
EUR 64.4 MILLION YEAR AGO
    * Q3 CONSOLIDATED NET LOSS OF EUR 122.9 MILLION VERSUS LOSS
OF EUR
112.8 MILLION YEAR AGO
    * Q3 OPERATING LOSS NARROWS TO EUR 29.3 MILLION VERSUS LOSS
OF EUR
82.4 MILLION YEAR AGO THANKS TO DECLINING SELLING EXPENSES
    * 9-MONTH OPERATING LOSS OF EUR 152.3 MILLION VERSUS LOSS OF
EUR
183.3 MILLION YEAR AGO
    * 9-MONTH CONSOLIDATED NET LOSS WIDENS TO EUR 480.5 MILLION
VERSUS
LOSS OF EUR 133.5 MILLION YEAR AGO, MAINLY DUE TO HIGHER FINANCE
EXPENSES
    * Q3 MONJUVI U.S. NET PRODUCT SALES OF $22.2 MILLION VERSUS
$22.0
MILLION YEAR AGO
    * Q3 SELLING EXPENSES DOWN AT EUR 23.5 MILLION VERSUS EUR
32.4
MILLION YEAR AGO

Further company coverage:  MORG.DE 
 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))